Unknown

Dataset Information

0

Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.


ABSTRACT:

SUBMITTER: Tiacci E 

PROVIDER: S-EPMC8550943 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10163281 | biostudies-literature
| S-EPMC4811324 | biostudies-literature
| S-EPMC7250239 | biostudies-literature
| S-EPMC6087717 | biostudies-literature
| S-EPMC10300288 | biostudies-literature
| S-EPMC3861900 | biostudies-literature
| S-EPMC4982774 | biostudies-literature
| S-EPMC7584966 | biostudies-literature
| S-EPMC3689585 | biostudies-literature
| S-EPMC4291160 | biostudies-literature